Skye Bioscience, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$58.2M | -$30.2M | -$34.7M | -$18.3M | -$7.8M |
| Operating expenses | $58.2M | $30.2M | $34.7M | $18.3M | $7.8M |
| Cash from operations | -$43.1M | -$25.2M | -$14.0M | -$12.7M | -$6.5M |
| Capital expenditure | $6,312 | $1.6M | $12,550 | $28,060 | $90,866 |
| Free cash flow | -$43.1M | -$26.8M | -$14.0M | -$12.8M | -$6.6M |
| Total assets | $28.3M | $72.8M | $11.9M | $9.1M | $9.9M |
| Total liabilities | $8.3M | $4.6M | $14.1M | $12.1M | $4.0M |
Shares outstanding 35.1M · Free float 34.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.